PMID- 36029160
OWN - NLM
STAT- MEDLINE
DCOM- 20221115
LR  - 20221115
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 109
IP  - 6
DP  - 2022 Dec
TI  - Activated prothrombin complex concentrate to treat bleeding events in acquired 
      hemophilia A: BAHAS study.
PG  - 686-695
LID - 10.1111/ejh.13853 [doi]
AB  - OBJECTIVE: Activated prothrombin complex concentrate (aPCC) is a bypassing agent 
      indicated to treat bleeds in patients with acquired hemophilia A (AHA). 
      Nevertheless, its efficacy and safety in the real-world setting have not often 
      been addressed. METHODS: We report the experience of Spanish reference centers 
      for coagulation disorders and from acquired hemophilia Spanish Registry (AHASR) 
      from August 2012 to February 2021. Follow-up period of 30 days after aPCC 
      withdrawal. RESULTS: Thirty patients with a median age of 70 years old, suffering 
      from 51 bleeds treated with aPCC were finally evaluated. As first-line treatment, 
      aPCC stopped bleeding in 13 of 14 (92.9%) cases. aPCC as the second line after 
      recombinant factor VIIa failure, stopped bleeding in all cases. In 17 patients, 
      aPCC was used far from initial bleed control as prophylaxis of rebleeding with 
      94% effectiveness. No thromboembolic episodes were communicated. One patient 
      developed hypofibrinogenemia, which did not prevent aPCC from halting bleeding. 
      No other serious adverse events possibly or probably associated with aPCC were 
      reported. CONCLUSIONS: This data support aPCC as hemostatic treatment in AHA with 
      high effectiveness and excellent safety profile in acute bleeds and as extended 
      use to prevent rebleedings, even in aging people with high cardiovascular risk.
CI  - (c) 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Mingot-Castellano, Maria E
AU  - Mingot-Castellano ME
AUID- ORCID: 0000-0001-9083-855X
AD  - Hematology Department, Hospital Universitario Virgen del Rocio, Instituto de 
      Biomedicina de Sevilla (IBIS), Sevilla, Spain.
AD  - Hematology Department, Hospital Regional Universitario de Malaga, Malaga, Spain.
FAU - Garcia-Candel, Faustino
AU  - Garcia-Candel F
AD  - Hematology Department, Hospital Virgen de la Arrixaca, Murcia, Spain.
FAU - Benitez-Hidalgo, Olga
AU  - Benitez-Hidalgo O
AUID- ORCID: 0000-0002-2883-9049
AD  - Hematology Department, Hospital Vall de Hebron, Barcelona, Spain.
FAU - Marco, Ana
AU  - Marco A
AD  - Hematology Department, Hospital General de Alicante, Alicante, Spain.
FAU - Mendez Navarro, Gala A
AU  - Mendez Navarro GA
AD  - Hematology Department, Hospital Marques de Valdecilla, Santander, Spain.
FAU - Perez-Montes, Rocio
AU  - Perez-Montes R
AD  - Hematology Department, Hospital Marques de Valdecilla, Santander, Spain.
FAU - Garcia Donas, Gloria
AU  - Garcia Donas G
AD  - Hematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
FAU - Canaro, Mariana
AU  - Canaro M
AD  - Hematology Department, Hospital Son Espases, Palma de Mallorca, Spain.
FAU - Paloma, Maria J
AU  - Paloma MJ
AD  - Hematology Department, Hospital Universitario Virgen del Camino, Pamplona, Spain.
FAU - Asenjo, Beatriz
AU  - Asenjo B
AD  - Hematology Department, Hospital Clinico Universitario San Carlos, Madrid, Spain.
FAU - Calle-Gordo, Victoria M
AU  - Calle-Gordo VM
AD  - Hematology Department, Hospital Torrecardenas, Almeria, Spain.
FAU - Gonzalez, Noelia P
AU  - Gonzalez NP
AD  - Hematology Department, Hospital Torrecardenas, Almeria, Spain.
FAU - Rodriguez Gonzalez, Ramon
AU  - Rodriguez Gonzalez R
AD  - Hematology Department, Hospital Severo Ochoa, Madrid, Spain.
FAU - Caparron-Miranda, Isabel S
AU  - Caparron-Miranda IS
AD  - Hematology Department, Hospital Universitario Virgen de la Victoria, Malaga, 
      Spain.
FAU - Quintana Paris, Laura
AU  - Quintana Paris L
AD  - Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrin, Las 
      Palmas de Gran Canaria, Spain.
FAU - Herrero, Sonia
AU  - Herrero S
AD  - Hematology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
FAU - Nunez, Ramiro
AU  - Nunez R
AD  - Hematology Department, Hospital Universitario Virgen del Rocio, Instituto de 
      Biomedicina de Sevilla (IBIS), Sevilla, Spain.
LA  - eng
GR  - Shire IIR-ES-002899/
PT  - Journal Article
DEP - 20220912
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Blood Coagulation Factors)
RN  - 9001-28-9 (Factor IX)
RN  - 9001-27-8 (Factor VIII)
RN  - 37224-63-8 (prothrombin complex concentrates)
RN  - 0 (Recombinant Proteins)
RN  - Factor 8 deficiency, acquired
SB  - IM
MH  - Aged
MH  - Humans
MH  - Blood Coagulation Factors/therapeutic use
MH  - Cost-Benefit Analysis
MH  - Factor IX/therapeutic use
MH  - Factor VIII/therapeutic use
MH  - *Hemophilia A/complications/drug therapy
MH  - Hemorrhage/etiology/drug therapy
MH  - Recombinant Proteins/therapeutic use
OTO - NOTNLM
OT  - acquired hemophilia
OT  - bleeding
OT  - bypass agent
OT  - coagulation disorders
OT  - inhibitors
OT  - prophylaxis
EDAT- 2022/08/28 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/08/27 06:15
PHST- 2022/08/19 00:00 [revised]
PHST- 2022/06/05 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/08/28 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/08/27 06:15 [entrez]
AID - 10.1111/ejh.13853 [doi]
PST - ppublish
SO  - Eur J Haematol. 2022 Dec;109(6):686-695. doi: 10.1111/ejh.13853. Epub 2022 Sep 
      12.